GRF:BME
Grifols SA Class A
€9,03
arrow_upward
+0,49%(+0,044) 1D
25 ມິ.ຖ., 14 ໂມງ 43 ນາທີ 16 ວິນາທີ GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRF...
Open
€9,05
High
€9,05
Low
€8,95
Mkt. cap
໕,໕໓ ຕື້
Avg. vol.
໒,໖໔ ລ້ານ
Volume
໕໑໐,໒໐ ພັນ
Dividend
໒,໕໗%
Quarterly dividend
€0,06
Ex-dividend date
30 ມິ.ຖ. 2026
P/E ratio
໑໓,໔໑
52-wk high
€13,70
52-wk low
€8,43
EPS
€0,67
Shares outstanding
໔໒໖,໑໓ ລ້ານ
No. of employees
໒໕ ພັນ
Open
€9,05
High
€9,05
Low
€8,95
Mkt. cap
໕,໕໓ ຕື້
Avg. vol.
໒,໖໔ ລ້ານ
Volume
໕໑໐,໒໐ ພັນ
Dividend
໒,໕໗%
Quarterly dividend
€0,06
Ex-dividend date
30 ມິ.ຖ. 2026
P/E ratio
໑໓,໔໑
52-wk high
€13,70
52-wk low
€8,43
EPS
€0,67
Shares outstanding
໔໒໖,໑໓ ລ້ານ
No. of employees
໒໕ ພັນ
News stories
From sources across the web
AD HOC NEWS
·
3 ມື້ກ່ອນ
Grifols Stock - weekly outlook with earnings and debt focus
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A
AI content may include mistakes. Learn more